Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

DUBLIN--(BUSINESS WIRE)--Sep 5, 2023--

Related Keywords

United Kingdom ,Bedford ,Massachusetts ,United States ,Ireland ,Cambridge ,Cambridgeshire ,Dublin ,Helen Cross ,Im Scott Perry ,Elaine Wirrell ,Eric Rojas ,Company Annual Report On Form ,Cook Children Medical Center ,Exchange Commission ,Stoke Therapeutics Inc ,Neurology Residency Training Program At Mayo Clinic ,John Justin Neurosciences Center ,Nasdaq ,International League Against Epilepsy ,International Epilepsy Congress ,University College London Institute Of Child Health ,Augmentation Of Nuclear Gene Output ,Augmentation Of Nuclear Gene Output Is Stoke ,Childhood Epilepsy ,Child Health ,Honorary Consultant ,Paediatric Neurology ,Dravet Syndrome ,Senior Vice President ,Clinical Pharmacology ,Digital Poster Presentation ,Ongoing Open Label ,United Kingdom Investigating Safety ,Drug Exposure ,Antisense Oligonucleotide ,Developmental Neuroscience Programme ,International League Against ,Previously Participated ,Scott Perry ,Genetic Epilepsy Clinic ,Cook Children ,Investigate Cognition ,Pediatric Epilepsy ,Mayo Clinic ,Adolescent Neurology Residency Training Program ,Targeted Augmentation ,Nuclear Gene Output ,Private Securities Litigation Reform Act ,Annual Report ,Stoke Media ,Investor Contacts ,Stoke Therapeutics ,Business Wire ,Region ,